desipramine has been researched along with Alzheimer Disease in 33 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "59 moderate Alzheimer patients with major depressive disorder were randomly divided into 3 groups (sertraline, venlafaxine and desipramine), treated for 12 weeks (150 mg maximum dose) and assessed by the Hamilton Depression Test (HRSD), the Mini Mental State Examination (MMSE) and the Barthel index at the week 0 and the 2(nd), 4(th), 8(th), 12(th) weeks thereafter." | 2.79 | Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. ( Abdollahian, E; Azarpazhooh, A; Haghighi, MB; Mokhber, N; Saghebi, A; Samadi, R; Soltanifar, A, 2014) |
| "Alzheimer's disease is the most common cause of dementia." | 1.42 | In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. ( Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 23 (69.70) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Shutske, GM | 1 |
| Pierrat, FA | 1 |
| Kapples, KJ | 1 |
| Cornfeldt, ML | 1 |
| Szewczak, MR | 1 |
| Huger, FP | 1 |
| Bores, GM | 1 |
| Haroutunian, V | 1 |
| Davis, KL | 1 |
| McKenna, MT | 1 |
| Proctor, GR | 1 |
| Young, LC | 1 |
| Harvey, AL | 1 |
| Marco-Contelles, J | 1 |
| León, R | 3 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 3 |
| Andrisano, V | 4 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Luque, FJ | 3 |
| Rodríguez-Franco, MI | 6 |
| López, B | 3 |
| López, MG | 4 |
| García, AG | 3 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 4 |
| Camps, P | 1 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 3 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 2 |
| Badia, A | 1 |
| Clos, MV | 2 |
| Mancini, F | 2 |
| Arce, MP | 4 |
| Dafni, T | 1 |
| González-Muñoz, GC | 2 |
| Pérez, C | 4 |
| Conde, S | 3 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 2 |
| Tang, H | 3 |
| Zhao, LZ | 1 |
| Zhao, HT | 2 |
| Huang, SL | 2 |
| Zhong, SM | 2 |
| Qin, JK | 1 |
| Chen, ZF | 2 |
| Huang, ZS | 2 |
| Liang, H | 2 |
| Chiriano, G | 1 |
| De Simone, A | 2 |
| Perez, DI | 2 |
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Legname, G | 1 |
| Martinez, A | 1 |
| Carloni, P | 1 |
| Roberti, M | 1 |
| Wang, ZY | 1 |
| Sun, Y | 2 |
| Chen, J | 1 |
| Chen, X | 1 |
| Huang, L | 3 |
| Li, X | 6 |
| Di Pietro, O | 1 |
| Pérez-Areales, FJ | 2 |
| Juárez-Jiménez, J | 1 |
| Espargaró, A | 2 |
| Pérez, B | 3 |
| Sabaté, R | 2 |
| Miao, H | 1 |
| Meng, F | 1 |
| Cahlíková, L | 1 |
| Štěpánková, Š | 1 |
| Chlebek, J | 1 |
| Šafratová, M | 1 |
| Hošt'álková, A | 1 |
| Opletal, L | 1 |
| Wang, H | 2 |
| Lu, Z | 1 |
| Zheng, X | 1 |
| Ni, W | 1 |
| Zhu, J | 2 |
| Fu, Y | 2 |
| Lian, F | 1 |
| Zhang, N | 1 |
| Li, J | 4 |
| Zhang, H | 2 |
| Mao, F | 2 |
| Wang, B | 1 |
| Wang, Z | 1 |
| Chen, H | 1 |
| Lu, CJ | 1 |
| Wei, S | 1 |
| Chen, W | 1 |
| Qin, J | 1 |
| Huangli, Y | 1 |
| Wang, L | 1 |
| Shen, Y | 1 |
| Xia, CL | 1 |
| Wang, N | 1 |
| Guo, QL | 1 |
| Liu, ZQ | 1 |
| Wu, JQ | 1 |
| Ou, TM | 1 |
| Tan, JH | 1 |
| Wang, HG | 1 |
| Li, D | 1 |
| Monjas, L | 1 |
| Gil, C | 1 |
| Hepnarova, V | 1 |
| Korabecny, J | 1 |
| Matouskova, L | 1 |
| Jost, P | 1 |
| Muckova, L | 1 |
| Hrabinova, M | 1 |
| Vykoukalova, N | 1 |
| Kerhartova, M | 1 |
| Kucera, T | 1 |
| Dolezal, R | 1 |
| Nepovimova, E | 1 |
| Spilovska, K | 1 |
| Mezeiova, E | 1 |
| Pham, NL | 1 |
| Jun, D | 1 |
| Staud, F | 1 |
| Kaping, D | 1 |
| Kuca, K | 1 |
| Soukup, O | 1 |
| Reis, J | 1 |
| Cagide, F | 1 |
| Valencia, ME | 1 |
| Teixeira, J | 1 |
| Bagetta, D | 1 |
| Uriarte, E | 1 |
| Oliveira, PJ | 1 |
| Ortuso, F | 1 |
| Alcaro, S | 1 |
| Borges, F | 1 |
| Hu, J | 1 |
| Pan, T | 1 |
| An, B | 1 |
| Li, Z | 1 |
| Turcu, AL | 2 |
| Barniol-Xicota, M | 1 |
| Pont, C | 1 |
| Pivetta, D | 1 |
| Sureda, FX | 2 |
| Vázquez, S | 2 |
| Jiang, X | 2 |
| Zhou, J | 1 |
| Wang, Y | 3 |
| Chen, L | 1 |
| Duan, Y | 1 |
| Huang, J | 2 |
| Liu, C | 2 |
| Chen, Y | 2 |
| Liu, W | 2 |
| Sun, H | 2 |
| Feng, F | 2 |
| Qu, W | 1 |
| Xing, C | 1 |
| Lyu, W | 1 |
| Wang, S | 1 |
| Li, Q | 1 |
| Chen, T | 1 |
| Huang, Y | 1 |
| Gong, Q | 1 |
| Xu, Y | 1 |
| You, H | 1 |
| Zhang, D | 2 |
| Companys-Alemany, J | 1 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 1 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Soto, D | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 1 |
| Mokhber, N | 1 |
| Abdollahian, E | 1 |
| Soltanifar, A | 1 |
| Samadi, R | 1 |
| Saghebi, A | 1 |
| Haghighi, MB | 1 |
| Azarpazhooh, A | 1 |
| Dias, IH | 1 |
| Mistry, J | 1 |
| Fell, S | 1 |
| Reis, A | 1 |
| Spickett, CM | 1 |
| Polidori, MC | 1 |
| Lip, GY | 1 |
| Griffiths, HR | 1 |
| Wang, DD | 1 |
| Yu, LP | 1 |
| Wu, MN | 1 |
| Sun, LN | 1 |
| Qi, JS | 1 |
| Lauterbach, EC | 1 |
| Victoroff, J | 1 |
| Coburn, KL | 1 |
| Shillcutt, SD | 1 |
| Doonan, SM | 1 |
| Mendez, MF | 1 |
| Kornhuber, J | 1 |
| Tripal, P | 1 |
| Reichel, M | 1 |
| Mühle, C | 1 |
| Rhein, C | 1 |
| Muehlbacher, M | 1 |
| Groemer, TW | 1 |
| Gulbins, E | 1 |
| Francis, BM | 1 |
| Yang, J | 1 |
| Hajderi, E | 1 |
| Brown, ME | 1 |
| Michalski, B | 1 |
| McLaurin, J | 1 |
| Fahnestock, M | 1 |
| Mount, HT | 1 |
| Odenheimer, GL | 1 |
3 reviews available for desipramine and Alzheimer Disease
| Article | Year |
|---|---|
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo | 2010 |
Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications.
Topics: Acid Ceramidase; Alzheimer Disease; Clinical Trials as Topic; Desipramine; Humans; Phosphodiesterase | 2010 |
Management of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Causality; Desipramine; Electroco | 1991 |
1 trial available for desipramine and Alzheimer Disease
| Article | Year |
|---|---|
Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antidepressive Agents; Cognition; Comorbidity; | 2014 |
29 other studies available for desipramine and Alzheimer Disease
| Article | Year |
|---|---|
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
Topics: Alzheimer Disease; Aminoacridines; Animals; Chemical Phenomena; Chemistry; Cholinesterase Inhibitors | 1989 |
Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Magnetic Resonance Spect | 1997 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood- | 2011 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Surviv | 2012 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra | 2012 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro | 2013 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B | 2014 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain | 2015 |
Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cell Line; Ch | 2016 |
Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Copper; Drug Design; Hu | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras | 2016 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase I | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug | 2018 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitor | 2019 |
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inh | 2020 |
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2021 |
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Choli | 2022 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Oxidized LDL lipids increase β-amyloid production by SH-SY5Y cells through glutathione depletion and lipid raft formation.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor | 2014 |
Desipramine improves depression-like behavior and working memory by up-regulating p-CREB in Alzheimer's disease associated mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents, Tricyclic; Cyclic AMP Resp | 2016 |
Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Aging; Alzheimer Disease; Amy | 2012 |